|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0010583,
umls-concept:C0016360,
umls-concept:C0026259,
umls-concept:C0087111,
umls-concept:C0439858,
umls-concept:C0679729,
umls-concept:C0746319,
umls-concept:C0950521,
umls-concept:C1516213,
umls-concept:C1518578,
umls-concept:C1522673,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1996-5-16
|
|
pubmed:abstractText |
362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 mg/m2), and fluorouracil (500 mg/m2; CNF). After a median follow-up of 51 months, 64 (36%) patients relapsed in the CMF group and 60 (33%) in the CNF group (p=0.8276). By Cox multivariate analysis, tumor size, menopausal status and number of involved nodes were retained as independently significant variables. Toxicities were remarkably similar in both groups. It appears that after a median follow-up of 51 months there is no significant difference in relapse-free survival between node-positive patients with breast cancer who received either 6 cycles of the conventional CMF or the CNF combination as adjuvant treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
pubmed-author:FahantidisEE,
pubmed-author:FountzilasGG,
pubmed-author:GennatasKK,
pubmed-author:GiannakakisTT,
pubmed-author:HainoglouDD,
pubmed-author:KatsohisKK,
pubmed-author:KlouvasGG,
pubmed-author:KolotasCC,
pubmed-author:KonstantarasCC,
pubmed-author:KosmidisPP,
pubmed-author:MakrantonakisPP,
pubmed-author:MylonakisNN,
pubmed-author:PavlidisNN,
pubmed-author:PolichronisAA,
pubmed-author:SemoglouCC,
pubmed-author:SkarlosDD,
pubmed-author:ToussisDD,
pubmed-author:TsavarisNN,
pubmed-author:TsiliakosSS,
pubmed-author:VassilarosSS,
pubmed-author:ZamboglouNN
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
137-46
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8604240-Adult,
pubmed-meshheading:8604240-Aged,
pubmed-meshheading:8604240-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8604240-Breast Neoplasms,
pubmed-meshheading:8604240-Chemotherapy, Adjuvant,
pubmed-meshheading:8604240-Cyclophosphamide,
pubmed-meshheading:8604240-Female,
pubmed-meshheading:8604240-Fluorouracil,
pubmed-meshheading:8604240-Follow-Up Studies,
pubmed-meshheading:8604240-Humans,
pubmed-meshheading:8604240-Methotrexate,
pubmed-meshheading:8604240-Middle Aged,
pubmed-meshheading:8604240-Mitoxantrone,
pubmed-meshheading:8604240-Remission Induction,
pubmed-meshheading:8604240-Survival Rate
|
|
pubmed:articleTitle |
Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study.
|
|
pubmed:affiliation |
1st Department of Internal Medicine, Oncology Section, AHEPA Hospital, Aristotle University, Thessaloniki, Greece.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
